Evidence map›Paper›PMID 31253118›Full record

ArticleBMC neurology2019

Fulminant Guillain-Barré syndrome showing severe pharyngeal-cervical-brachial weakness in the recovery phase: a case report.

Yoshitsugu Nakamura, Mikiko Motoki, Takahiko Hirose, Takafumi Hosokawa, Shimon Ishida, Shigeki Arawaka

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Subacute combined degeneration of the spinal cord with concomitant autoimmune disease: report of 2 cases.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yoshitsugu NakamuraDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan.
Mikiko MotokiDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan.
Takahiko HiroseDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan.
Takafumi HosokawaDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan.
Shimon IshidaDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan.
Shigeki ArawakaDepartment of Internal Medicine IV, Division of Neurology, Osaka Medical College, 2-7 Daigakumachi, Takatsukishi, Osaka, 569-8686, Japan. sarawaka@osaka-med.ac.jp.
Osaka Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFulminant Guillain-Barré syndrome (GBS) is characterized clinically by rapid progression of severe symptoms, such as the absence of brainstem reflexes, complete tetraplegia and respiratory arrest. The clinical course of fulminant GBS remains unclear. Here, we report a patient with fulminant GBS, who showed severe weakness of the pharyngeal-cervical-branchial (PCB) area in the recovery phase. CASE PRESENTATION: A 38-year-old man rapidly developed fulminant GBS. In blood examination, he was positive for a broad range of anti-ganglioside antibodies, including anti-GQ1b, GT1a, GT1b, GD1a, GD1b and GD3 IgG antibodies. We performed immunosuppressive therapies using intravenous immunoglobulin and intravenous methylprednisolone. Although disturbance of consciousness and weakness of the distal upper and lower limbs improved gradually, weakness of the oropharynx, neck, and proximal upper limbs were resistant to these therapies. Anti-GT1a IgG antibodies remained persistently positive. Consequently, mechanical ventilation and tube feeding were required for 7 and 10 months, respectively. Two years later, weakness of the proximal upper limbs and mild respiratory dysfunction remained as sequelae.

conclusionAnti-GT1a IgG antibodies are known to be detected in patients with the PCB variant of GBS. In fulminant GBS, the persistent presence of anti-GT1a IgG antibodies may be associated with occurrence of severe PCB-like weakness in the recovery phase.

Indexed as

AdultAutoantibodiesDisease ProgressionGangliosidesGuillain-Barre SyndromeHumansMaleMuscle WeaknessNeckOropharynxUpper ExtremityAutoantibodiesGangliosidesAnti-GT1a antibodyCase reportFulminantGuillain-Barré syndromePharyngeal-cervical-brachial weakness

Identifiers

PMID31253118
PMCPMC6598254
OpenAlexW2954409107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.